secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-06-16T11:18:22+00:00
Accession:  0001534120-26-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027
--------------------------------------------------------------------------------

- AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.
- IND submission for AVTX-010 expected in the first half of 2027.
- Building on abdakibart Phase 2 LOTUS data and the IL-1β pathway conviction.
- CEO cites less frequent dosing as key driver for physician and patient preference.
- Follows transformational financing completed in May 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/0001534120-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/avtx-20260616.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer